References
- Yin L, Svigos K, Gutierrez D, et al. Low-dose oral minoxidil increases hair density and thickness in androgenetic alopecia: a retrospective analysis of 60 patients. J Eur Acad Dermatol Venereol. 2022;36(3):e200–e202.
- Gupta AK, Venkataraman M, Talukder M, et al. Finasteride for hair loss: a review. J Dermatolog Treat. 2021;33:1938–1946.
- Gupta AK, Talukder M, Venkataraman M, et al. Minoxidil: a comprehensive review. J Dermatolog Treat. 2021;20:1–11.
- Choi GS, Kim JH, Oh SY, et al. Safety and tolerability of the dual 5-alpha reductase inhibitor dutasteride in the treatment of androgenetic alopecia. Ann Dermatol. 2016;28(4):444–450.
- Macdonald G. GSK Japan delays alopecia drug launch after Catalent manufacturing halt. 2015. [cited 2022 03 March]. Available from: https://www.outsourcing-pharma.com/Article/2015/12/03/GSK-Japan-delays-alopecia-drug-launch-after-Catalent-manufacturing-halt
- Tsunemi Y, Irisawa R, Yoshiie H, et al. Long‐term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol. 2016;43(9):1051–1058.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84:1644–1651.
- Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, et al. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol. 2019;81(2):648–649.
- FDA databse: Drugs@FDA. FDA-approved drugs. 2022. [cited 2022 March 03]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021319
- Nusbaum AG, Rose PT, Nusbaum BP. Nonsurgical therapy for hair loss. Facial Plast Surg Clin North Am. 2013;21(3):335–342.
- Rogers NE, Gupta AK. Medical treatments for male and female pattern hair loss. In: Unger WP, editor. Hair transplantation. 6 ed. London: Informa Healthcare; p. 38–46.
- Zito PM, Bistas KG, Syed K. Finasteride. 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513329/
- Scharman EJ. Minoxidil. Encyclopedia of toxicology. 2nd ed. Amsterdam, Netherlands: Elsevier; 2005. p. 114–115.
- Fleishaker J, Andreadis N, Welshman I, et al. The pharmacokinetics of 2.5‐to 10‐mg oral doses of minoxidil in healthy volunteers. J Clin Pharmacol. 1989;29(2):162–167.
- PROPECIA® (finasteride) tablets for oral use (FDA label). 2021. [cited 2021 October 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020788s028lbl.pdf
- AVODART (dutasteride) soft gelatin capsules: highlights of prescribing information (FDA label). 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s032lbl.pdf
- Clissold SP, Heel RC. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica. Drugs. 1987;33(2):107–122.
- Minoxidil: basics, side effects, reviews & more (GoodRx). 2021. [cited 2022 February 22]. Available from: https://www.goodrx.com/minoxidil/what-is.
- Lowenthal DT, Affrime MB. Pharmacology and pharmacokinetics of minoxidil. J Cardiovasc Pharmacol. 1980;2:S93–S106.
- Pfizer Loniten (Minoxidil) tablet, 2.5 mg & 10 mg, for oral use (RxTx) [Internet]. 2013. [cited 2021 April 26]. Available from: https://www-e-therapeutics-ca.myaccess.library.utoronto.ca/search.
- Luo D, Han L, Gao S, et al. LINCS dataset-based repositioning of dutasteride as an anti-neuroinflammation agent. Brain Sci. 2021;11(11):1411.
- AVODART® (dutasteride) soft capsule package insert. 2003. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
- Buhl AE, Waldon DJ, Baker CA, et al. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990;95(5):553–557.
- GlaxoSmithKline AVODART® (dutasteride) capsule, 0.5 mg (RxTx) [Internet]. 2013. [cited 2022 February 16]. Available from: https://www-e-therapeutics-ca.myaccess.library.utoronto.ca/search
- Foye W, Lemke T. Foye's principles of medicinal chemistry. Philadelphia (PA): Lippincott Williams and Wilkins; 2008.
- Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol. 1990;17(5):276–281.
- Kwack MH, Kang BM, Kim MK, et al. Minoxidil activates β-catenin pathway in human dermal papilla cells: a possible explanation for its anagen prolongation effect. J Dermatol Sci. 2011;62(3):154–159.
- Lachgar S, Charveron M, Gall Y, et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407–411.
- Oh HA, Kwak J, Kim BJ, et al. Migration inhibitory factor in conditioned medium from human umbilical cord blood-derived mesenchymal stromal cells stimulates hair growth. Cells. 2020;9(6):1344.
- Choi BY. Targeting wnt/β-catenin pathway for developing therapies for hair loss. Int J Mol Sci. 2020;21(14):4915.
- Galbraith GM, Thiers BH. In vitro suppression of human lymphocyte activity by minoxidil. Int J Dermatol. 1985;24(4):249–251.
- Shorter K, Farjo NP, Picksley SM, et al. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008;22(6):1725–1736.
- Semalty M, Semalty A, Joshi GP, et al. Hair growth and rejuvenation: an overview. J Dermatolog Treat. 2011;22(3):123–132.
- Pekmezci E, Türkoğlu M. Minoxidil acts as an antiandrogen: a study of 5α-reductase type 2 gene expression in a human keratinocyte cell line. Acta Dermatovenerolog Croatic. 2017;25(4):271–271.
- Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6(9):S31.
- Godoy A, Kawinski E, Li Y, et al. 5α‐Reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate. 2011;71(10):1033–1046.
- Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002;198(1–2):89–95.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–1023.
- Vahabi-Amlashi S, Layegh P, Kiafar B, et al. A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss. Dermatol Ther. 2021;34(6):e15131.
- Ramos PM, Sinclair RD, Kasprzak M, et al. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial. J Am Acad Dermatol. 2020;82(1):252–253.
- Vastarella M, Cantelli M, Patrì A, et al. Efficacy and safety of oral minoxidil in female androgenetic alopecia. Dermatol Ther. 2020;33(6):e14234.
- Pirmez R, Salas-Callo CI. Very-low-dose oral minoxidil in male androgenetic alopecia: a study with quantitative trichoscopic documentation. J Am Acad Dermatol. 2020;82(1):e21–e22.
- Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment. Dermatol Ther (Heidelb). 2020;10(6):1345–1357.
- Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143(4):804–810.
- Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride male pattern hair loss study group. J Am Acad Dermatol. 1998;39(4):578–589.
- Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999;40(6):930–937.
- Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41(4):555–563.
- Shanshanwal S, Dhurat R. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017;83(1):47.
- Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252–258.
- Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–498.e3.
- Gupta AK, Venkataraman M, Talukder M, et al. Relative efficacy of minoxidil and the 5-α reductase inhibitors in androgenetic alopecia treatment of male patients: a network Meta-analysis. JAMA Dermatol. 2022;158(3):266.
- Gupta AK, Hall D, Talukder M, et al. There is a positive dose-dependent association between low-dose oral minoxidil and its efficacy for androgenetic alopecia: findings from a systematic review with Meta-regression analyses. Skin Appendage Disord. 2022;1–7.
- Jha AK, Sonthalia S, Zeeshan M, et al. Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia. J Am Acad Dermatol. 2020;83(5):1491–1493.
- FDA Adverse Events Reporting System (FAERS) [Internet]. FDA. 2021. [cited 27 April 2022]. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
- Sanabria BD, Palmegiani E, Seron AF, et al. Prospective cardiovascular evaluation with 24-h holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022.
- Parsa Mohebi Hair Restoration: Minoxidil FAQ. 2022. [cited 2022 26 July]. Available from: https://parsamohebi.com/hair-loss/medical-treatment/minoxidil-rogaine/minoxidil-faq/#
- Fierro MC, Yafi FA, Reisman Y. Post-finasteride syndrome. Textbook of rare sexual medicine conditions. Berlin, Germany: Springer Nature; 2022. p. 65.
- Alhetheli GI, Alrashidi FH, Alhammad SH. Post-Finasteride syndrome: current views and where do we stand? Ann Med Health Sci Res. 2022;12:12–18.
- Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(09):1220–1223.
- Nguyen D-D, Marchese M, Cone EB, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2021;157(1):35–42.
- Nguyen D-D, Herzog P, Cone EB, et al. Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: a pharmacovigilance analysis of VigiBase. J Am Acad Dermatol. 2022.
- Gupta AK, Carviel J, MacLeod MA, et al. Assessing finasteride-associated sexual dysfunction using the FAERS database. J Eur Acad Dermatol Venereol. 2017;31(6):1069–1075.
- Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the prostate cancer prevention trial. J Natl Cancer Inst. 2007;99(18):1375–1383.
- Goodman PJ, Tangen CM, Darke AK, et al. Long-term effects of finasteride on prostate cancer mortality. N Engl J Med. 2019;380(4):393–394.
- Bautista OM, Kusek JW, Nyberg LM, Jr, et al. Study design of the medical therapy of prostatic symptoms (MTOPS) trial. Control Clin Trials. 2003;24(2):224–243.
- MHRA public assessment report: the risk of male breast cancer with finasteride. London: MHRA; 2009. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/852392/Finasteride_risk_of_male_breast_cancer.pdf
- Organon PROPECIA® (finasteride) Tablet, 1 mg (RxTx) [Internet]. 2021. [cited 16-02-2022]. Available from: https://www-e-therapeutics-ca.myaccess.library.utoronto.ca/search
- Amory JK, Wang C, Swerdloff RS, et al. The effect of 5α-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92(5):1659–1665.
- PROSCAR® (finasteride) tablets for oral use (FDA label). 2021. [cited 2022 26 July]. Available from: file:///C:/Users/mesba/Downloads/020180s047lbl.pdf
- Laborde E, Brannigan RE. Effect of 1‐mg dose of finasteride on spermatogenesis and pregnancy. J Androl. 2010;31(2):e1–e2.
- Can men who are trying for a pregnancy take Propecia? (Dr Fox). 2013. [cited 2022 27 July]. Available from: https://www.doctorfox.co.uk/news/can-men-who-are-trying-for-a-pregnancy-take-propecia/#:∼:text=Finasteride%20is%20found%20in%20semen,too%20small%20to%20be%20harmful
- Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–1202.
- Dutasteride pregnancy and breastfeeding warnings. 2022. [cited 2022 27 July]. Available from: https://www.drugs.com/pregnancy/dutasteride.html
- Adovart (dutasteride) package insert, 0.5 mg soft capsule. 2020. Available from: https://www.medicines.org.uk/emc/files/pil.6758.pdf